Brainsway Ltd
TASE:BWAY
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
937.1
2 026
|
| Price Target |
|
We'll email you a reminder when the closing price reaches ILS.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Brainsway Ltd
Cost of Revenue
Brainsway Ltd
Cost of Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
B
|
Brainsway Ltd
TASE:BWAY
|
Cost of Revenue
-$8.3m
|
CAGR 3-Years
-18%
|
CAGR 5-Years
-18%
|
CAGR 10-Years
-44%
|
|
|
Nano-X Imaging Ltd
NASDAQ:NNOX
|
Cost of Revenue
-$16.5m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Inmode Ltd
NASDAQ:INMD
|
Cost of Revenue
-$77.8m
|
CAGR 3-Years
-18%
|
CAGR 5-Years
-34%
|
CAGR 10-Years
N/A
|
|
|
Sisram Medical Ltd
HKEX:1696
|
Cost of Revenue
-$136.9m
|
CAGR 3-Years
-13%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
N/A
|
|
|
S
|
Sofwave Medical Ltd
TASE:SOFW
|
Cost of Revenue
-$12.8m
|
CAGR 3-Years
-97%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
E
|
Epitomee Medical Ltd
TASE:EPIT
|
Cost of Revenue
-$260k
|
CAGR 3-Years
3%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Brainsway Ltd
Glance View
Brainsway Ltd. is a commercial stage medical device company, which focuses on the development and sale of non-invasive neuromodulation products using the proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) technology for the treatment of major depressive disorder (MDD) and obsessive-compulsive disorder (OCD). The firm primarily offers Transcranial Magnetic Stimulation (TMS) system, a medical device that enables direct non-invasive activation of deep brain structures. Its TMS system uses magnetic pulses to stimulate neurons and consequently modulates the physiological activity of the brain. TMS system is used in various clinical applications including: major depressive disorders, obsessive-compulsive disorder, smoking addiction and others various psychiatric, neurological, and addiction disorders.
See Also
What is Brainsway Ltd's Cost of Revenue?
Cost of Revenue
-8.3m
USD
Based on the financial report for Dec 31, 2023, Brainsway Ltd's Cost of Revenue amounts to -8.3m USD.
What is Brainsway Ltd's Cost of Revenue growth rate?
Cost of Revenue CAGR 10Y
-44%
Over the last year, the Cost of Revenue growth was -17%. The average annual Cost of Revenue growth rates for Brainsway Ltd have been -18% over the past three years , -18% over the past five years , and -44% over the past ten years .
You don't have any saved screeners yet
